Literature DB >> 15476240

Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells.

Jau-Ling Suen1, Ya-Hui Chuang, Bor-Yu Tsai, Peter M Yau, Bor-Luen Chiang.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by the existence of a heterogeneous group of autoantibodies directed against intact nuclear structures, such as nucleosomes. The most prominent of these autoantibodies are those directed against double-stranded DNA (dsDNA) and histones. The majority are of the IgG isotype and show affinity maturation, both of which are known hallmarks of T cell help. Much evidence suggests that the nucleosome is a major candidate autoantigen in SLE. In this study, a novel strategy was used to identify the critical CD4+ T cell autoepitopes in nucleosomes. In addition, peptide-based therapy was then performed in a lupus animal model.
METHODS: Bone marrow (BM)-derived dendritic cells (DCs) were used to examine the self-T cell responses against nucleosomes and to characterize the T cell epitope(s) of nucleosomes in (NZB x NZW)F1 (BWF1) mice.
RESULTS: Several potential auto-T cell epitopes of core histone proteins (H2A, H2B, H3, and H4) were identified. Nucleosome-pulsed BM-derived DCs elicited release of interleukin-4 and interferon-gamma, representing a Th0 (i.e., mixed Th1 and Th2) pattern of cytokine production. In addition, intradermal immunization of BWF1 mice with the H3(111-130) peptide not only suppressed the level of anti-dsDNA and anti-single-stranded DNA IgG, but also significantly delayed the progress of glomerulonephritis in lupus-prone BWF1 mice.
CONCLUSION: These results will help in understanding how pathogenic autoimmune responses develop in spontaneous SLE. This may potentially open the way to T cell-based immunotherapy for lupus. Copyright 2004 American College of Rheumatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476240     DOI: 10.1002/art.20520

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

2.  The histone peptide H4 71-94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms.

Authors:  Hee-Kap Kang; Ming-Yi Chiang; Michael Liu; Diane Ecklund; Syamal K Datta
Journal:  J Clin Immunol       Date:  2011-02-03       Impact factor: 8.317

3.  Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity.

Authors:  Li Zhang; Anne M Bertucci; Rosalind Ramsey-Goldman; Elizabeth Randall Harsha-Strong; Richard K Burt; Syamal K Datta
Journal:  Clin Immunol       Date:  2013-08-23       Impact factor: 3.969

Review 4.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

5.  Induction of IL-10 producing CD4+ T cells with regulatory activities by stimulation with IL-10 gene-modified bone marrow derived dendritic cells.

Authors:  C-L Fu; Y-H Chuang; H-Y Huang; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 6.  Autoantibodies in systemic lupus erythematosus.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2011-12-23       Impact factor: 3.651

7.  Th17/Treg Ratio and Disease Activity in Systemic Lupus Erythematosus.

Authors:  Yuliasih Yuliasih; Lita Diah Rahmawati; Rizki Maulidya Putri
Journal:  Caspian J Intern Med       Date:  2019

Review 8.  Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future).

Authors:  Syamal K Datta
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.